泻火平突散治疗急性期甲状腺相关眼病
|
摘要
目的:观察泻火平突散治疗急性期甲状腺相关眼病(thyroid-associated ophthalmopathy,TAO)的临床疗效。方法:将66例急性期TAO患者按随机数字表法分为对照组和观察组各33例。对照组给予综合治疗,观察组在对照组治疗基础上给予泻火平突散。两组疗程均为12周。比较两组患者眼部主要症状、中医证候积分、临床活动度评分(clinical activity score,CAS)、软组织炎症分级(NOSPECS)的变化。结果:①临床疗效:对照组有效率为63.64%,观察组有效率为81.82%,两组比较,差异有统计学意义(P<0.05)。②中医症状积分:两组患者治疗后积分均下降,观察组治疗后低于同期对照组,差异均有统计学意义(P<0.05)。③NOSPECS分级:两组患者治疗后分级均显著下降,观察组分级下降更为明显,差异均有统计学意义(P<0.05)。④CAS评分:两组患者治疗后积分均下降,观察组治疗后低于同期对照组,差异均有统计学意义(P<0.05)。结论:泻火平突散治疗急性期TAO疗效显著,可降低患者中医症状积分、CAS评分及NOSPECS分级。
Objective:To observe the clinical efficacy of Xiehuo Pingtu Powder in treatment of acute thyroid-associated ophthalmopathy(TAO).Methods:Sixty-six patients with acute phase TAO were randomly divided into control group and observation group,33 cases each.The control group was given comprehensive treatment,and the observation group was given the diarrhea level on the basis of the treatment of the control group.Both groups were treated for 12 weeks.The main symptoms of the eye,TCM syndrome scores,clinical activity score(CAS),and soft tissue inflammation grade(NOSPECS) were compared between the two groups.Results:①Clinical efficacy:The effective rate of the control group was 63.64%,and the effective rate of the observation group was 81.82%.The difference between the two groups was statistically significant(P<0.05).②TCM syndrome scores:The scores of the two groups of patients decreased after treatment,and the observation group was lower than the control group after treatment,the difference was statistically significant(P<0.05).③NOSPECS classification:The scores of the two groups were significantly decreased after treatment,and the decrease of the component level was more obvious,and the difference was statistically significant(P<0.05).④CAS score:The scores of the two groups were decreased after treatment.The observation group was lower than the control group after treatment,and the difference was statistically significant(P<0.05).Conclusion:Xiehuo Pingtu Powder has a significant effect on the treatment of acute phase TAO,which can reduce the TCM syndrome score,CAS score and NOSPECS classification.
Objective:To observe the clinical efficacy of Xiehuo Pingtu Powder in treatment of acute thyroid-associated ophthalmopathy(TAO).Methods:Sixty-six patients with acute phase TAO were randomly divided into control group and observation group,33 cases each.The control group was given comprehensive treatment,and the observation group was given the diarrhea level on the basis of the treatment of the control group.Both groups were treated for 12 weeks.The main symptoms of the eye,TCM syndrome scores,clinical activity score(CAS),and soft tissue inflammation grade(NOSPECS) were compared between the two groups.Results:①Clinical efficacy:The effective rate of the control group was 63.64%,and the effective rate of the observation group was 81.82%.The difference between the two groups was statistically significant(P<0.05).②TCM syndrome scores:The scores of the two groups of patients decreased after treatment,and the observation group was lower than the control group after treatment,the difference was statistically significant(P<0.05).③NOSPECS classification:The scores of the two groups were significantly decreased after treatment,and the decrease of the component level was more obvious,and the difference was statistically significant(P<0.05).④CAS score:The scores of the two groups were decreased after treatment.The observation group was lower than the control group after treatment,and the difference was statistically significant(P<0.05).Conclusion:Xiehuo Pingtu Powder has a significant effect on the treatment of acute phase TAO,which can reduce the TCM syndrome score,CAS score and NOSPECS classification.
引文
[1]EDMUNDS M R,HUNTBACH J A,DURRANI O M.Are ethnicity,social grade,and social deprivation associated with severity of thyroid-associated ophthalmopathy[J]?Ophthalmic Plast Reconstr Surg,2014,30(3):241-245.
[2]NAIK V M,NAIK M N,GOLDBERG R A,et al.Immuno pathogenesis of Thyroid eye disease:emerging paradigms[J].Surv Ophthamol,2010,55(3):215-226.
[3]宁光,周智广.内科学[M].北京:人民卫生出版社,2014:73-74.
[4]潘文奎.中医药治疗甲状腺机能亢进症信息与分析[J].中国中医药信息杂志,1995,2(6):14.
[5]BAHN R S.Graves′ ophthalmopathy[J].N Engl J Med,2010,362(8):726-738.
[6]陈欢欢,杨涛.甲状腺相关眼病发病机制研究进展[J].中国实用内科杂志,2015,35(7):561-564.
[7]WEILER D L.Thyroid eye disease:a review[J].Clin Exp Optom,2017,100(1):20-25.
[8]VAN STEENSEL L,DIK WA.The orbital fibroblast:a key player and tar-get for therapy in Graves′ ophthalmopathy[J].Orbit,2010,29(4):202-206.
[9]王韧琰,钟勇.甲状腺相关眼病研究进展[J].国际眼科杂志,2009,9(7):1334-1337.
[10]BARTALENA L,PIANTANIDA E.Cigarette smoking:number one enemyfor Graves ophthalmopathy[J].Pol Arch Med Wewn,2016,126(6):725-726.
[11]吕圭源.药理学[M].北京:中国中医药出版社,2011:243-244.
[12]ROOTMAN D B.Orbital decompression for thyroid eye disease[J].Surv Ophthalmol,2018,63(1):86-104.
[13]高艺倬,李辉.甲状腺相关眼病治疗新进展[J].基础医学与临床,2018,38(12):1795-1798.
[14]易京红.滋阴平肝清热法治疗甲状腺相关眼病探讨[J].北京中医药,2018,37(11):1084-1085.
[15]郑艳秋,马艳梅,徐文媛.基于经典理论与文献资料探讨甲状腺相关眼病中医诊疗[J].中国地方病防治杂志,2018,33(6):653-654.
[2]NAIK V M,NAIK M N,GOLDBERG R A,et al.Immuno pathogenesis of Thyroid eye disease:emerging paradigms[J].Surv Ophthamol,2010,55(3):215-226.
[3]宁光,周智广.内科学[M].北京:人民卫生出版社,2014:73-74.
[4]潘文奎.中医药治疗甲状腺机能亢进症信息与分析[J].中国中医药信息杂志,1995,2(6):14.
[5]BAHN R S.Graves′ ophthalmopathy[J].N Engl J Med,2010,362(8):726-738.
[6]陈欢欢,杨涛.甲状腺相关眼病发病机制研究进展[J].中国实用内科杂志,2015,35(7):561-564.
[7]WEILER D L.Thyroid eye disease:a review[J].Clin Exp Optom,2017,100(1):20-25.
[8]VAN STEENSEL L,DIK WA.The orbital fibroblast:a key player and tar-get for therapy in Graves′ ophthalmopathy[J].Orbit,2010,29(4):202-206.
[9]王韧琰,钟勇.甲状腺相关眼病研究进展[J].国际眼科杂志,2009,9(7):1334-1337.
[10]BARTALENA L,PIANTANIDA E.Cigarette smoking:number one enemyfor Graves ophthalmopathy[J].Pol Arch Med Wewn,2016,126(6):725-726.
[11]吕圭源.药理学[M].北京:中国中医药出版社,2011:243-244.
[12]ROOTMAN D B.Orbital decompression for thyroid eye disease[J].Surv Ophthalmol,2018,63(1):86-104.
[13]高艺倬,李辉.甲状腺相关眼病治疗新进展[J].基础医学与临床,2018,38(12):1795-1798.
[14]易京红.滋阴平肝清热法治疗甲状腺相关眼病探讨[J].北京中医药,2018,37(11):1084-1085.
[15]郑艳秋,马艳梅,徐文媛.基于经典理论与文献资料探讨甲状腺相关眼病中医诊疗[J].中国地方病防治杂志,2018,33(6):653-654.